page contents
Photo by JESHOOTS.com on Pexels.com

Proteostasis Therapeutics Stock Price Skyrockets From Positive FDA Phase 1 Results

Proteostasis Therapeutics Announces Positive Preliminary FDA Phase 1 Results

(By Glenford S Robinson)

Proteostasis Therapeutics, Inc. (NASDAQ: PTI), stock price skyrocketed 300% today, October 18, 2017 on positive Phase 1 study news from the Food and Drug Administration (FDA), which stated that the company’s proprietary doublet PTI-801 and PTI-808 cystic fibrosis research medicines have proven safe at the dosage level administered to research volunteers. The study volunteers consist of 20 to 100 individuals, which includes healthy people and those with the disease.

Proteostasis Therapeutics, Inc. (PTI) is a clinical stage biopharmaceutical company focused on developing therapies effective against cystic fibrosis (CF), a diseased caused by the dysfunctional processing of protein in the human body.

Armed with over 450 issued patents and a topnotch group of research scientists in technology, pharmaceuticals, and healthcare, PTI is confident that it can support its claim as the Inventor of Digital Medicine. In fact, a positive Phase 1 result of its cystic fibrosis research drug study is a strong indication that the company is capable of supporting such claim, as the undisputed Inventor of Digital Medicine.

The company claimed to be the Inventor of Digital Medicine, simply because it has developed a new category of pharmaceuticals that measures the effectiveness of medication treatment, help physicians in improving clinical outcomes and thus, help patients accomplish health goals.

Proteostasis Therapeutics plans to bring its new digital solution to healthcare providers by coordinating its efforts with leading health systems and pharmaceutical companies which will increase access to better insights, optimized therapies, and reduced costs.

© 2018 mstardom.com. Mstardom Finance does not provide investment advice. All rights reserved.

Check Also

Where can I get business financing?

Horizon Technology Finance Provides Investment Portfolio Update Increases Portfolio Size with $24 Million in Loan Originations; Grows Committed Backlog to $47 Million

"During the third quarter, we experienced solid investment activity, increasing the size of our portfolio and expanding our committed backlog for the second consecutive quarter," said Gerald A. Michaud, President of Horizon. "Our success funding seven loans, totaling more than $24 million, and growing our committed backlog to $47 million underscores the strong demand for our venture debt products to growing life science and technology companies. We believe Horizon will continue to benefit from a robust pipeline of investment opportunities and is well positioned to deliver long-term, disciplined portfolio growth, while ensuring credit quality remains strong."

Doctor is warning against side effects of medicine

FDA Adds Boxed Warning for Increased Risk of Death with Gout Medicine Uloric (Febuxostat)

Uloric was FDA-approved in 2009 to treat a type of arthritis called gout in adults. Gout happens when a naturally occurring substance in the body called uric acid builds up and causes sudden attacks of redness, swelling, and pain in one or more joints. Uloric works by lowering uric acid levels in the blood. Gout is a chronic disease that affects approximately 8.3 million adults in the U.S.1 The number of medicines to treat gout is limited and there is an unmet need for treatments for this disease.

Litigation Photo

Immune Design (IMDZ) Alert: Johnson Fistel Investigates Proposed Sale of Immune Design Corp.; Are Immune Design Shareholders Getting a Fair Deal?

The investigation concerns whether the Immune Design board failed to satisfy its duties to the Company shareholders, including whether the board adequately pursued alternatives to the acquisition and whether the board obtained the best price possible for Immune Design shares of common stock. Nationally recognized Johnson Fistel is investigating whether the proposed deal represents adequate consideration, especially given that one Wall Street analyst has a $9.00 price target on the stock and the Company has approximately $100 million in cash and no long-term debt.

Mergers and Acquisitions

Merck to Acquire Immune Design; Acquisition Bolsters Capabilities in Vaccine Development for Infectious Diseases and Cancer

“Scientists at Immune Design have established a unique portfolio of approaches to cancer immunization and adjuvant systems designed to enhance the ability of a vaccine to protect against infection, which could meaningfully improve vaccine development," said Dr. Roger M. Perlmutter, president, Merck Research Laboratories. “This acquisition builds upon Merck’s industry-leading programs that harness the power of the immune system to prevent and treat disease.”

FDA Authorizes First Interoperable Insulin Pump Intended to Allow Patients to Customize Treatment Through their Individual Diabetes Management Devices

“Diabetes is a complicated disease that requires close monitoring and carefully tailored treatments. We’ve heard from the patient community that having the ability to customize their own diabetes management devices is important to them. Advances in digital health make more tailored approaches to diabetes care possible,” said FDA Commissioner Scott Gottlieb, M.D. “The marketing authorization of the first ACE insulin pump intended for interoperable use has the potential to aid patients who seek more individualized diabetes therapy systems and opens the door for developers of future connected diabetes devices to get other safe and effective products to patients more efficiently. Because the FDA’s action creates a new regulatory classification, future ACE insulin pumps will be able to go through the more efficient 510(k) review process, helping to advance this innovative technology. We’re committed to advancing new ways to accelerate the development of innovations that can improve patient care while strengthening our pre- and post-market tools for determining the safety and effectiveness of these new technologies.

California Jury finds Johnson & Johnson Baby Powder Contained Asbestos, was Defective, and its Risks were “Known or Knowable” to the Company

For its part, Reuters has stood by its reporting, citing multiple tests from 1971 to the early 2000s finding asbestos in Johnson's Baby Powder and talc from mines which supplied J&J.

Teva Pharmaceutical Stock (TEVA) Trading Higher Today on FDA Approval of Its Seizure Drug Sabril for Adults and Pediatric Epilepsy Patients

Complex partial seizures, a common type of seizures, start in a specific area of the brain and can affect consciousness. Typically, complex partial seizures last between 30 and 90 seconds, and are often followed by a period of disorientation, confusion and/or fatigue.

%d bloggers like this: